Invasive bladder cancer in the eastern townships of Canada

Muscle Invasice Bladder Cancer (MIBC)


Bladder cancer is the second most common genitourinary malignant disease in the world. Bladder cancer comes in two forms, superficial and invasive. Invasive bladder cancer, referred to as muscle invasive bladder cancer (MIBC) is deadly and current treatment options are surgery and chemotherapy. Unfortunately, surgery involves removing the bladder and results in complications and patients often succumb to problems with normal urination. Chemotherapy is ineffective. Patients diagnosed with MIBC, after traditional surgery and chemotherapy, have a 47% 5-year survival rate (Kaufman et al., Lancet, 2009). 


Thanks to the help from patients in the Eastern Townships and support from the medical experts such as physicians, nurses, clinical coordinators, together we discovered that MIBC patients preferentially have a protein called interleukin-5 receptor alpha (aka CD125) relative to healthy patients with healthy bladders or non-life threatening bladder cancer. These results were published in the prestigious journal OncoImmunology. The Leyton team is now developing targeted therapeutics against CD125.

IL-5Ra clinical paper.jpg